DCA can modulate the expression of breast cancer type 1 susceptibility protein (BRCA1) and the estrogen receptor and, through these, can control drug sensitivity of ovarian cancer cells (Table 6) [281]. The gene discussed is BRCA1; the disease is ovarian carcinoma.